Peripartum cardiomyopathy

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Cardiology Network

Discuss Peripartum cardiomyopathy further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy that is defined as a deterioration in cardiac function presenting between the last month of gestation and up to five months post-partum.

As with other forms of dilated cardiomyopathy, PPCM involves decrease of the left ventricular ejection fraction with associated congestive heart failure and increased risk of atrial and ventricular arrhythmias and even sudden cardiac death.

The etiology of postpartum cardiomyopathy is unknown.

Risk factors

In the US the prevalence is estimated to be 1 case per 1300-15,000 live births.

The incidence of peripartum cardiomyopathy is increased in women over the age of 30, in twin pregnancies, in multiparous women, in women with gestational hypertension, those who have received tocolytic therapy, and in african americans.

Clinical Features (History)

Pregnancy itself brings about some features that suggest cardiac insufficiency. Symptoms such as dyspnoea, dizziness, orthopnoea and decreased exercise tolerance are often normal findings in pregnancy.

Moreover, the normal cardiac physiology changes dramatically in the gravid female. Blood volume increases progressively from 6-8 weeks gestation (pregnancy) and reaches a maximum at approximately 32-34 weeks with little change thereafter. During the first trimester cardiac output is 30-40% higher than in the non-pregnant state; there is also an approximately 35% increase in stroke volume, a 15% increase in HR and a steady decrease in vascular resistance.

Since this is excellent cover for a developing condition, often there are no extreme or notable symptoms until several days post-partum when the most notable symptoms become pulmonary edema with resultant breathing difficulties(dysnopea), serious energy depletion performing simple tasks such as walking, standing or even sitting up for extended periods, and sudden cardiac arrest.

If these conditions appear after a woman has been discharged from clinical care the possibility of mortality is greatly increased.


The dyspnoea is described usually by women as the inability to take a deep breath to get enough air into her lungs. It is thought that the hormonally mediated (progesterone) hyperventilation seen in pregnancy is the cause.

In PPCM the symptoms secondary to acute onset of heart failure seen are similar to patients with systolic dysfunction who are not pregnant. These symptoms include cough, orthopnoea, paroxysmal nocturnal dyspnoea, fatigue, palpitations, haemoptysis and chest pain. These symptoms mimic many normal pregnant women who cannot tolerate lying flat, have significant pedal edema, complain of shortness of breath and dyspnea but have no heart disease.

The challenge facing physicians is to differentiate between these two groups and diagnose women with PPCM sooner than later as early intervention has shown benefit and may save lives.

Prognosis

Mortality rates range anywhere between 9% and 56%. About 50 to 60 percent of women with PPCM demonstrate improvement or total recovery in their left ventricular function within 6 months of diagnosis. The remainder tend to have either stabilization of their ventricular function or worsening (requiring cardiac transplantation).1

Women are strongly discouraged form subsequent pregnancies as numerous studies have demonstrated recurrence of the disease.

The New York Peripartum Cardiomyopathy Study Group is an ongoing registry seeking to answer many of the questions left unanswered because of the rarity of the disease. For more information about the study, one can visit [3].

Treatment for this disease varies widely reflecting the range of severity. While some patients with severe left ventricular dysfunction (less than 35%) may proceed to cardiac tranplant or require an automated internal cardiac defibrillator (AICD) and standard heart failure therapy, others may return to normal cardiac function and reuqire little, if any, additional medical therapy. However, all women should be strongly discouraged from having subsequent pregnancies.

Treatment

Treatment for the disease is similar to treatment for congestive heart failure. Delivery is the recommeded overall treatment to decrease the volume load, improve ventricular function and simplify the medical management of these patients.

References

1. Ravikishore AG, Kaul UA, Sethi KK, Khalilullah M. Peripartum cardiomyopathy: prognostic variables at initial evaluation. Int J Cardiol. 1991 Sep;32(3):377-80. (Medline abstract) 2. Ro, Angela; Frishman, William. Cardiology in Review 2006;14: 35–42

WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools
related articles